希腊动脉粥样硬化协会血脂异常诊断与治疗指南（2023年）执行摘要
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.
作者信息
Katsiki N, Filippatos Td, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A, Garoufi A, Rallidis L, Richter D, Nomikos T, Kolovou G, Kypreos K, Chrysohoou C, Tziomalos K, Skoumas I, Koutagiar I, Attilakos A, Papagianni M, Boutari C, Kotsis V, Pitsavos C, Elisaf M, Tsioufis K, Liberopoulos E
机构信息
Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.
School of Medicine, European University Cyprus, Nicosia, Cyprus.
出版信息
Atheroscler Plus. 2024 Feb 17;55:74-92. doi: 10.1016/j.athplu.2024.01.004. eCollection 2024 Mar.
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.
动脉粥样硬化性心血管疾病（ASCVD）仍然是全球主要的死亡原因，因此其预防、早期诊断和治疗至关重要。血脂异常是一个主要的ASCVD风险因素，在不同的临床环境中都应得到充分管理。希腊动脉粥样硬化协会2023年指南重点关注ASCVD风险评估、血脂异常的实验室评估、新型降脂药物以及女性、老年人和家族性高胆固醇血症、急性冠状动脉综合征、心力衰竭、中风、慢性肾病、糖尿病、自身免疫性疾病和非酒精性脂肪性肝病患者的脂质紊乱的诊断和治疗。还讨论了他汀类药物不耐受情况。
Zotero 插件